Anti-IFN-alpha Human ELISA

Summary

Antibodies to IFN-α were detected in patients with various autoimmune disorders and in the serum of patients with systemic lupus erythematosus. Spontaneous antibodies to IFN-a were shown to occur in sera of various cancer patients. Neutralizing IFN-α antibodies were also found in cerebrospinal fluids and sera of acute aseptic meningitis patients as well as in patients with chronic polyarthritis.

Research topic

Autoimmunity, Cytokines and chemokines and related molecules, Immune Response, Infection and Inflammation

Assay format

Sandwich ELISA, HRP-labelled antibody

Applications

Cell culture supernatant, Plasma, Serum, Urine

Sample requirements

20 µl

Storage/Shipping

2–8°C

Calibration Curve

Calibration range

3.2  – 200 ng/ml

Limit of detection

1.38 ng/ml

Intra-assay

CV = 3.3%

Inter-assay

CV = 4.1%

Spiking Recovery

92%

Dilution Linearity

104 %

References to summary

• Middelhoff G, Boll I. A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. Ann Hematol. 1992 May;64 (5):207-9
• Craxi A, Di Marco V, Volpes R, Palazzo U. Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis. Hepatogastroenterology. 1988 Dec;35 (6):304-5
• Aitchison R, Allen P, Schey S, Newland AC. Anti-interferon antibodies in alpha interferon treated patients with chronic myeloid leukaemia. Br J Haematol. 1991 Jul;78 (3):465-7
• Figlin RA, Itri LM. Anti-interferon antibodies: a perspective. Semin Hematol. 1988 Jul;25 (3 Suppl 3):9-15
• Jacobs SL, Kelsey DK. Antibodies in patients with hairy-cell leukemia receiving alpha-2b interferon. N Engl J Med. 1986 Nov 27;315 (22):1418
• Thurmond LM, Brand CM, Leventhal BG, Finter NB, Johnston JM. Antibodies in patients with recurrent respiratory papillomatosis treated with lymphoblastoid interferon. J Lab Clin Med. 1991 Sep;118 (3):232-40
• Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol. 1985 Nov;3 (11):1522-8
• Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines--friends or foes?. Immunol Today. 1990 May;11 (5):167-9
• Pozzetto B, Mogensen KE, Tovey MG, Gresser I. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis. 1984 Nov;150 (5):707-13
• von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H. Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet. 1987 Sep 12;2 (8559):635-6
• Oberg K, Alm GV. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. J Interferon Res. 1989 Sep;9 Suppl 1:S45-9
• Dummer R, Muller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer. 1991 May 1;67 (9):2300-4
• von Wussow P, Freund M, Dahle S, Jakschies D, Poliwode H, Deicher H. Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia. N Engl J Med. 1988 Nov 3;319 (18):1226-7
• Levy-Koenig RE, Mundy MJ, Paucker K. Immunology of interferons. I. Immune response to protective and nonprotective interferons. J Immunol. 1970 Apr;104 (4):785-90
• Itri LM, Sherman MI, Palleroni AV, Evans LM, Tran LL, Campion M, Chizzonite R. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a. J Interferon Res. 1989 Sep;9 Suppl 1:S9-15
• Porres JC, Carreno V, Ruiz M, Marron JA, Bartolome J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol. 1989 May;8 (3):351-7
• Prummer O. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer. 1993 Mar 1;71 (5):1828-34
• de Wit R, Bakker PJ, Danner SA, Goudsmit J, Veenhof KH. Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma. Int J STD AIDS. 1990 Jul;1 (4):256-8
• Steinmann GG, God B, Rosenkaimer F, Adolf G, Bidlingmaier G, Fruhbeis B, Lamche H, Lindner J, Patzelt E, Schmahling C, et al.. Low incidence of antibody formation due to long-term interferon-alpha 2c treatment of cancer patients. Clin Investig. 1992 Feb;70 (2):136-41
• Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am J Med. 1986 Feb;80 (2):223-8
• Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, Angarano G, Dianzani F, Pastore G. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver. 1993 Jun;13 (3):146-50
• Ichimura H, Shimase K, Tamura I, Kaneto E, Kurimura O, Aramitsu Y, Kurimura T. Neutralizing antibody and interferon-alpha in cerebrospinal fluids and sera of acute aseptic meningitis. J Med Virol. 1985 Mar;15 (3):231-7
• Mogensen KE, Daubas P, Gresser I, Sereni D, Varet B. Patient with circulating antibodies to alpha-interferon. Lancet. 1981 Nov 28;2 (8257):1227-8
• von Wussow P, Jakschies D, Hartung K, Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int. 1988;8 (5):225-30
• Freund M, von Wussow P, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, et al.. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol. 1989 Jul;72 (3):350-6
• Figlin RA, deKernion JB, Mukamel E, Palleroni AV, Itri LM, Sarna GP. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol. 1988 Oct;6 (10):1604-10
• Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med. 1982 May;96 (5):549-56
• Antonelli G, Currenti M, Turriziani O, Riva E, Dianzani F. Relative frequency of nonneutralizing antibodies to interferon (IFN) in hepatitis patients treated with different IFN-alpha preparations. J Infect Dis. 1992 Mar;165 (3):593-4
• Steis RG, Smith JW 2nd, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med. 1988 Jun 2;318 (22):1409-13
• Gugliotta L, Catani L, Vianelli N, Mattioli Belmonte M, Cascione ML, Bendani M, Fanin R, Michieli MG, Baccarani M, Tura S. [Essential thrombocythemia: therapy with alpha interferons]. Haematologica. 1991 Jun;76 Suppl 3:374-7
• Faradzhev ZG, Samsonov VA, Parfenova TM, Malinovskaia VV. [The interferon status of patients with lymphoproliferative diseases of the skin and Kaposi's sarcoma]. Vestn Dermatol Venerol. 1990; (7):4-7

By research topic:

• Autoimmunity
• Cytokines and chemokines and related molecules
• Immune Response, Infection and Inflammation

By molecule:

• anti-IFN-alpha